Department of Dermatology, University of Wisconsin-Madison, United States.
School of Medicine and Public Health, Endocrinology and Reproductive Physiology Graduate Training Program, University of Wisconsin-Madison, Madison WI 53706, United States; King Saud bin Abdulaziz University for Health Sciences, Riyadh 11481, Saudi Arabia.
Semin Cancer Biol. 2018 Apr;49:20-28. doi: 10.1016/j.semcancer.2017.10.008. Epub 2017 Oct 24.
Melanoma remains an important health concern, given the steady increase in incidence and acquisition of resistance to systemic therapies. The receptor for advanced glycation end products (RAGE) initially identified for its binding to advanced glycation end products was subsequently acknowledged as a pattern recognition receptor given its ability to recognize similar structural elements within numerous ligands. Recent studies have elucidated a plausible role of RAGE in melanoma progression through modulation of inflammatory, proliferative and invasive cellular responses. Several of its ligands including the S100 proteins and HMGB1 are being investigated for their involvement in melanoma metastasis and as potential biomarkers of the disease. Targeting RAGE signaling represents a viable therapeutic strategy which remains underexplored in cutaneous malignancies. Here we have summarized current knowledge on the functionality of RAGE with special focus on specific ligands enumerated in various in vitro and in vivo melanoma models.
黑色素瘤仍然是一个重要的健康关注点，因为其发病率的稳步上升以及对全身治疗的耐药性的获得。晚期糖基化终产物受体（RAGE）最初因其与晚期糖基化终产物的结合而被识别，随后因其能够识别众多配体中的类似结构元件而被认为是一种模式识别受体。最近的研究阐明了 RAGE 通过调节炎症、增殖和侵袭性细胞反应在黑色素瘤进展中的可能作用。其几种配体，包括 S100 蛋白和 HMGB1，正在被研究其在黑色素瘤转移中的作用以及作为疾病的潜在生物标志物。靶向 RAGE 信号代表一种可行的治疗策略，但在皮肤恶性肿瘤中仍未得到充分探索。在这里，我们总结了 RAGE 功能的最新知识，特别关注各种体外和体内黑色素瘤模型中列举的特定配体。
